Royalty Report: Medical, Supply, Surgical – Collection: 282939

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Medical
  • Supply
  • Surgical
  • Wound Care
  • Drugs
  • Cancer
  • Assay
  • Device
  • Tissue
  • Pain
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 282939

License Grant
The University hereby grants to Licensee a royalty-bearing, exclusive right and license under Licensed Subject Matter to manufacture, have manufactured, use and sell Licensed Products, to practice any method, process or procedure within the Patent Rights or the Technology Rights, and to otherwise exploit the Licensed Subject Matter, within the Licensed Territory for use within the Licensed Field.
License Property
U.S. 843,485 – Photopolymerizable Biodegradable Hydrogels as Tissue Contracting Materials and Controlled-Release Carriers

Technology Rights shall mean any and all rights in any technical information, know-how, process, procedure, composition, device, method, formula, protocol, technique, software, design, drawing or data relating to biomedical hydrogels or surface coatings which is not covered by the Patent Rights but which is necessary for practicing an invention, discovery or information covered by the Patent Rights, conceived or reduced to practice either prior to the effective date, or after the effective date and arising out of or in connection with the research program, and which Board has or may have the right to license or sublicense to Licensee under this License Agreement.

Field of Use
Licensed Field shall mean treatment of any medical condition of humans including without limitation treatment of post-surgical adhesions and other fibrosis or scarring conditions, treatment by means of leave-behind materials after open and other less invasive surgical procedures (such as localized drug delivery vehicles, adhesives, sealers, glues and polymers) treatment by means of localized drug release, and treatment by arterial plugging after angioplasty or other percutaneous procedures in interentional cardiology by means of angioplasty catheters of any type.

The Licensee develops, manufactures and commercializes synthetic, absorbable, liquid surgical sealants based on the Company's proprietary polymer technology.

IPSCIO Record ID: 26781

License Grant
Licensor, who shares an operating officer with Licensee, hereby grants to Licensee a license solely in the Field of Use under Licensed Patents to make, have made, use and sell any Licensed Product and to practice any Licensed Method solely in the Field of Use throughout the Territory. Such license shall be exclusive within the Territory in the Field of Use.  All Fields of Use, except for and specifically excluding any applications, devices or methods designed to seal arterial puncture sites following angiography, angioplasty and/or other cardiac procedures.
License Property
This agreement is related to U.S. Pat. No. 5,941,897, U.S. Pat. No. 5,486,195; and U.S. Pat. No 5,725,551.

This is technology where the arteriotomy can be sealed by delivery of a patient specific autologous fibrin glue to a debrided, synthesized area adjacent to the extravascular opening of the arteriotomy.

Field of Use
All FIELDS OF USE, except for and specifically excluding any applications, devices or methods designed to seal arterial puncture sites following angiography, angioplasty and/or other cardiac procedures.

IPSCIO Record ID: 27345

License Grant
The Company has been granted three United States patents relating to the use of tissue on a removable backing which cover the sleeve configuration of Peri- Strips, the combination of tissue with a surgical stapling gun, and methods of performing a surgical procedure to remove diseased tissue.
License Property
Patent relates to Peri-Strips Dry covering the application of buttressing material (tissue or other synthetic material) onto a surgical stapler for purposes of reinforcing a surgical fastener suture line utilizing an adhesive substance and a positional and pressure equalization device to accomplish the adherence of the tissue to the surgical suturing device.

IPSCIO Record ID: 286069

License Grant
The University grants to the Canadian Licensee an exclusive license under Licensed Subject Matter to manufacture, have manufactured, use and/or sell licensed products within licensed territory for use within licensed field and, will extend to Universitys undivided interest in any licensed subject matter developed during the term of this agreement and jointly owned by University and Licensee.
License Property
Licensed subject matter means inventions and discoveries covered by patent rights or technology rights within licensed Field.

Technology rights shall mean University rights in any technical information, know-how, processes, procedures, compositions, devices, methods, formulae, protocols, techniques, software, designs, drawings or data created by the inventors before the Effective Date relating to the use of liposomal vinca alkaloids which are not covered by patent rights but which are necessary for practicing the inventions covered patent rights.

The patents are for The Use of Liposomal Vincristine in Order to Circumvent Toxicity and Allow Administration of Higher Doses of Drug, and,  Compositions and Methods for Treating Lymphoma.

Field of Use
The licensed field means cancer therapy.

IPSCIO Record ID: 29043

License Grant
Licensor hereby grants to Licensee a license solely in the Field of Use under Licensed Patents to make, have made, use and sell any Licensed Product and to practice any Licensed Method solely in the Field of Use throughout the Territory.
License Property
The agreement relates to U.S. Pat. No. 5,594,1897, U.S. Pat. No. 5,486,195; and U.S. Pat. No 5,725,551.
Field of Use
FIELDS OF USE, except for and specifically excluding any applications, devices or methods designed to seal arterial puncture sites following angiography, angioplasty and/or other cardiac procedures.

IPSCIO Record ID: 203427

License Grant
Licensor grants to Company, an affiliate, an exclusive, worldwide, non-transferable license, with the right to sublicense, to the Intellectual Property to make, have made, modify, import, use, offer to sell, sell and have sold Products and perform and have performed processes under the Intellectual Property, solely in the Field.  The parties are entering into a Stock Purchase Agreement of even date.
License Property
The intellectual property and patents include, but are not limited to, Purification of structurally ordered recombinant protein polymers, Construction of synthetic DNA and its use in large polypeptide synthesis, High molecular weight collagen-like protein polymers, Synthetic proteins as implantables, Protein-enriched thennoplastics, and, Tissue Adhesive Using Synthetic Crosslinking.
Field of Use
The Field shall mean human or veterinary applications involving treatment, repair and/or diagnosis of conditions of the spine; provided that with respect to any Intellectual Property covering covalently crosslinked or adhesive protein polymer formulations (including without limitation, drug delivery formulations) the Field shall mean all orthopaedic applications, including treatment or diagnosis of deformities of the musculoskeletal system, which includes all of the bones and cartilages of the body and associated muscle attachments.

The Company is to develop and commercialize an injectable protein-based formulation for the repair of spinal disks damaged either by injury or aging. Based on Licensor's proprietary tissue adhesive technology, the product under development has potential to be an effective outpatient surgical treatment for chronic low back pain.

IPSCIO Record ID: 369243

License Grant
For the CoSeal Sealant Units Exclusive Distribution, Sales and Marketing Rights,  Licensors of the United States, Switzerland and Canada grant
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in the Sealant Territory; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in the Sealant Territory during the term of this Distribution and License Agreement.

For the CoSeal Sealant Option, Licensor grants an option (the CoSeal Sealant Option)
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in Japan; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in Japan.

For the CoSeal Adhesion Prevention Units Exclusive Distribution, Sales and Marketing Rights, Licensor grants
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the Adhesion Prevention Territory; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the Adhesion Prevention Territory during the term of this Distribution and License Agreement.

For the CoSeal Adhesion Prevention Option, Licensor grants to an option (the CoSeal Adhesion Prevention Option)
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the United States; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the United States.

For the CoSeal Accessories Exclusive Rights, Licensor grants
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Accessories in the Field in the Territory; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import the CoSeal Accessories in the Field in the Territory.

License Property
The trademarks include COSEAL©, ADHIBIT™, and, ANGIOTECHKNOWLEDGY™.

CoSeal Ingredients shall mean the two derivatized polyethylene glycol ingredients, designated COH102 and COH206

CoSeal Adhesion Prevention Unit shall mean a CoSeal Adhesion Prevention Product sold in combination with a CoSeal Adhesion Prevention Device.

CoSeal Devices shall mean, collectively, as the context requires, both or either of the CoSeal Adhesion Prevention Devices and/or the CoSeal Sealant Devices.

CoSeal Unit shall mean, collectively, as the context requires, both or either of the CoSeal Sealant Unit and/or the CoSeal Adhesion Prevention Unit.

CoSeal Sealant Unit shall mean a CoSeal Sealant Product sold in combination with a CoSeal Sealant Device.

CoSeal Sealant Product shall mean a product containing the CoSeal Ingredients that is the subject matter of a Regulatory Filing for use as a tissue sealant, adhesive or glue, has been or is approved by one or more Regulatory Authorities for use as a tissue sealant, adhesive or glue, or that is in development or sold for use as a tissue sealant, adhesive or glue.

Field of Use
CoSeal is indicated for use in vascular reconstructions to achieve adjunctive ·hemostasis by mechanically sealing areas of leakage.  CoSeal is designed to rapidly seal tissue surfaces, suture lines and synthetic grafts during surgery.

Field shall mean human therapeutic use for any and all tissue sealing, adhesive, glue or adhesion prevention barrier indications but shall specifically exclude any use (i) in Hemostat indications; (ii) for tissue regeneration indications; (iii) as an osteobiologic for skeletal repair an non-pharmacologic devices for osteoarthritis treatment,; (iv) as a urinary incontinence product and for the treatment of urinary incontinence; or (v) as an ostomy product.

IPSCIO Record ID: 203328

License Grant
Pursuant to this agreement, Licensor, an individual, has assigned his entire right, title and interest in, to and under the inventions described in the 925 application to Licensee.

Licensee is hereby granted and shall have a non-exclusive, perpetual, irrevocable, worldwide license to make, have made, modify, reproduce, display, use and sell such Item as part or in connection with such inventions.

Licensor grants to Licensee an exclusive option to obtain an exclusive, worldwide license to any Licensor Technology.

License Property
Licensor has assigned his entire right, title and interest in, to and under the inventions described in U.S. patent application. Serial No. 09/425,925 (the ''925 application'), entitled, 'Local Prevention or Amelioration of Pain from Surgically Closed Wounds,' which issued as U.S. Patent No. 6,383,511 (the ''511 Patent') to Cassel, as the inventor.

The term Licensors Technology means all copyrightable material, notes, records, inventions, improvements, developments, discoveries and trade secrets conceived, made by or discovered by Licensor outside of the performances of his services.

The Product means any composition of matter, material, device, apparatus, or system developed by Licensee for the treatment of pain from surgically closed wounds, which the making, using, offering for sale, sale or importation by an unlicensed third party, would infringe one or more issued claims of a Patent.

Field of Use
This agreement is for the field of surgical wound pain management.
LidoPAIN SP is a sterile prescription analgesic patch designed to provide sustained topical delivery of lidocaine to a post-surgical or post-traumatic sutured wound while also providing a sterile protective covering for the wound.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.